Given the positive regulatory role of HGF/c-MET axis in multiple pro-survival signals, and the observation that knockdown of c-MET reverses these effects, the HGF/c-MET axis emerges as a promising therapeutic target in CLL. The gene discussed is MET; the disease is B-cell chronic lymphocytic leukemia.